secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-033947
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track
------------------------------------------------------------------------

- FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.
- Cash $160.7M at Dec 31, 2023; subsequent $287.5M gross from Feb 2024 offering.
- Phase 2b 72-week data: sustained reductions in Gd-IgA1, hematuria, UPCR with stable eGFR; Phase 3 topline 1H 2025.
- Appointed Robert M. Brenner, M.D. as CMO and William D. Turner as CDO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/0000950170-24-033947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/vera-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer